Outcomes assessment following treatment of spasmodic dysphonia with botulinum toxin

M. S. Courey, C. G. Garrett, C. R. Billante, R. E. Stone, M. D. Portell, Timothy Smith, J. L. Netterville

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Spasmodic dysphonia (SD), a disabling focal dystonia involving the laryngeal musculature, is most commonly treated by the intramuscular injection of botulinum toxin (BTX). Although the treatment is well tolerated and generally produces clinical voice improvement, it has never been statistically shown to alter the patient's perception of voice quality or general health. Declining resources for medical care mandate that treatment outcomes be documented. A prospective analysis of the effects of BTX on the patient's perception of voice and general health was undertaken. The Voice Handicap Index (VHI) and Short Form 36 (SF-36) surveys were administered to patients before treatment and 1 month after. Pretreatment and posttreatment scores were analyzed with a Student's t-test. On the VHI, improvements in the patients' perception of their functional, physical, and emotional voice handicap reached statistical significance (p ≤ .0005). On the SF-36, patients had statistically significant improvements in mental health (p ≤ .03) and social functioning (p ≤ .04). Treatment of SD with BTX significantly lessened the patients' perception of dysphonia. In addition, it improved their social functioning and their perception of their mental health. These outcome measures justify the continued treatment of SD with BTX.

Original languageEnglish (US)
Pages (from-to)819-822
Number of pages4
JournalAnnals of Otology, Rhinology and Laryngology
Volume109
Issue number9
StatePublished - 2000
Externally publishedYes

Fingerprint

Dysphonia
Botulinum Toxins
Outcome Assessment (Health Care)
Mental Health
Therapeutics
Voice Quality
Dystonic Disorders
Intramuscular Injections
Health
Students

Keywords

  • Abductor
  • Adductor
  • Botulinum toxin
  • Dystonia
  • Spasmodic dysphonia
  • Voice Handicap Index

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Courey, M. S., Garrett, C. G., Billante, C. R., Stone, R. E., Portell, M. D., Smith, T., & Netterville, J. L. (2000). Outcomes assessment following treatment of spasmodic dysphonia with botulinum toxin. Annals of Otology, Rhinology and Laryngology, 109(9), 819-822.

Outcomes assessment following treatment of spasmodic dysphonia with botulinum toxin. / Courey, M. S.; Garrett, C. G.; Billante, C. R.; Stone, R. E.; Portell, M. D.; Smith, Timothy; Netterville, J. L.

In: Annals of Otology, Rhinology and Laryngology, Vol. 109, No. 9, 2000, p. 819-822.

Research output: Contribution to journalArticle

Courey, MS, Garrett, CG, Billante, CR, Stone, RE, Portell, MD, Smith, T & Netterville, JL 2000, 'Outcomes assessment following treatment of spasmodic dysphonia with botulinum toxin', Annals of Otology, Rhinology and Laryngology, vol. 109, no. 9, pp. 819-822.
Courey, M. S. ; Garrett, C. G. ; Billante, C. R. ; Stone, R. E. ; Portell, M. D. ; Smith, Timothy ; Netterville, J. L. / Outcomes assessment following treatment of spasmodic dysphonia with botulinum toxin. In: Annals of Otology, Rhinology and Laryngology. 2000 ; Vol. 109, No. 9. pp. 819-822.
@article{92659166cad743d5b3f263ec98f998d2,
title = "Outcomes assessment following treatment of spasmodic dysphonia with botulinum toxin",
abstract = "Spasmodic dysphonia (SD), a disabling focal dystonia involving the laryngeal musculature, is most commonly treated by the intramuscular injection of botulinum toxin (BTX). Although the treatment is well tolerated and generally produces clinical voice improvement, it has never been statistically shown to alter the patient's perception of voice quality or general health. Declining resources for medical care mandate that treatment outcomes be documented. A prospective analysis of the effects of BTX on the patient's perception of voice and general health was undertaken. The Voice Handicap Index (VHI) and Short Form 36 (SF-36) surveys were administered to patients before treatment and 1 month after. Pretreatment and posttreatment scores were analyzed with a Student's t-test. On the VHI, improvements in the patients' perception of their functional, physical, and emotional voice handicap reached statistical significance (p ≤ .0005). On the SF-36, patients had statistically significant improvements in mental health (p ≤ .03) and social functioning (p ≤ .04). Treatment of SD with BTX significantly lessened the patients' perception of dysphonia. In addition, it improved their social functioning and their perception of their mental health. These outcome measures justify the continued treatment of SD with BTX.",
keywords = "Abductor, Adductor, Botulinum toxin, Dystonia, Spasmodic dysphonia, Voice Handicap Index",
author = "Courey, {M. S.} and Garrett, {C. G.} and Billante, {C. R.} and Stone, {R. E.} and Portell, {M. D.} and Timothy Smith and Netterville, {J. L.}",
year = "2000",
language = "English (US)",
volume = "109",
pages = "819--822",
journal = "Annals of Otology, Rhinology and Laryngology",
issn = "0003-4894",
publisher = "Annals Publishing Company",
number = "9",

}

TY - JOUR

T1 - Outcomes assessment following treatment of spasmodic dysphonia with botulinum toxin

AU - Courey, M. S.

AU - Garrett, C. G.

AU - Billante, C. R.

AU - Stone, R. E.

AU - Portell, M. D.

AU - Smith, Timothy

AU - Netterville, J. L.

PY - 2000

Y1 - 2000

N2 - Spasmodic dysphonia (SD), a disabling focal dystonia involving the laryngeal musculature, is most commonly treated by the intramuscular injection of botulinum toxin (BTX). Although the treatment is well tolerated and generally produces clinical voice improvement, it has never been statistically shown to alter the patient's perception of voice quality or general health. Declining resources for medical care mandate that treatment outcomes be documented. A prospective analysis of the effects of BTX on the patient's perception of voice and general health was undertaken. The Voice Handicap Index (VHI) and Short Form 36 (SF-36) surveys were administered to patients before treatment and 1 month after. Pretreatment and posttreatment scores were analyzed with a Student's t-test. On the VHI, improvements in the patients' perception of their functional, physical, and emotional voice handicap reached statistical significance (p ≤ .0005). On the SF-36, patients had statistically significant improvements in mental health (p ≤ .03) and social functioning (p ≤ .04). Treatment of SD with BTX significantly lessened the patients' perception of dysphonia. In addition, it improved their social functioning and their perception of their mental health. These outcome measures justify the continued treatment of SD with BTX.

AB - Spasmodic dysphonia (SD), a disabling focal dystonia involving the laryngeal musculature, is most commonly treated by the intramuscular injection of botulinum toxin (BTX). Although the treatment is well tolerated and generally produces clinical voice improvement, it has never been statistically shown to alter the patient's perception of voice quality or general health. Declining resources for medical care mandate that treatment outcomes be documented. A prospective analysis of the effects of BTX on the patient's perception of voice and general health was undertaken. The Voice Handicap Index (VHI) and Short Form 36 (SF-36) surveys were administered to patients before treatment and 1 month after. Pretreatment and posttreatment scores were analyzed with a Student's t-test. On the VHI, improvements in the patients' perception of their functional, physical, and emotional voice handicap reached statistical significance (p ≤ .0005). On the SF-36, patients had statistically significant improvements in mental health (p ≤ .03) and social functioning (p ≤ .04). Treatment of SD with BTX significantly lessened the patients' perception of dysphonia. In addition, it improved their social functioning and their perception of their mental health. These outcome measures justify the continued treatment of SD with BTX.

KW - Abductor

KW - Adductor

KW - Botulinum toxin

KW - Dystonia

KW - Spasmodic dysphonia

KW - Voice Handicap Index

UR - http://www.scopus.com/inward/record.url?scp=0033757911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033757911&partnerID=8YFLogxK

M3 - Article

C2 - 11007083

AN - SCOPUS:0033757911

VL - 109

SP - 819

EP - 822

JO - Annals of Otology, Rhinology and Laryngology

JF - Annals of Otology, Rhinology and Laryngology

SN - 0003-4894

IS - 9

ER -